Pfizer said on Monday a combination of its breast cancer drug, Ibrance, and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial. Ibrance is Pfizer’s blockbuster treatment and is already approved as a combination with endocrine therapy for use in breast cancer patients. The…
